Please note this application is under active development. If you spot any errors or something isn't working, please contact us at evidence.service@wales.nhs.uk.

Smoking reduction interventions for smoking cessation

Lindson N et al (2019)

Cochrane Database of Systematic Reviews - 10.1002/14651858.CD013183.pub2.

Evidence Categories

  • Care setting: Healthcare Setting
  • Care setting: Community setting
  • Care setting: Educational Setting
  • Population group: Adults
  • Population group: Pre existing health condition
  • Population group: Children & Young adults
  • Population group: Current / previous history of substance misuse
  • Intervention: Bupropian
  • Intervention: Cognitive Behaviour Therapy
  • Intervention: Self-Help Materials
  • Intervention: Motivational Interviewing
  • Intervention: Behaviour Support
  • Intervention: Other Pharmacotherapies
  • Intervention: Nicotine Replacement Therapy
  • Intervention: Varenicline
  • Outcome: Smoking cessation
  • Outcome: Changes to smoking rates

Type of Evidence

Systematic Review

Aims

To assess the effect of reduction-to-quit interventions on long-term smoking cessation.

Findings

The authors identified 51 trials with 22,509 participants. Most recruited adults from the community using media or local advertising. People enrolledin the studies typically smoked an average of 23 cigarettes a day.

The authors identified very low-certainty evidence, limited by risk of bias, inconsistency and imprecision, comparing the effect of reduction-to-quit interventions with no treatment on cessation rates (RR 1.74, 95% CI 0.90 to 3.38; I2 = 45%; 6 studies, 1599 participants). However,when comparing reduction-to-quit interventions with abrupt quitting (standard care) the authorsfound evidence that neither approach resulted in superior quit rates (RR 1. 01, 95% CI 0.87 to 1.17; I2 = 29%; 22 studies, 9219 participants). The authors judged this estimate to be of moderate certainty, due to imprecision.

Subgroup analysis provided some evidence (P = 0.01, I2 = 77%) that reduction-to-quit interventions may result in more favourable quit rates than abrupt quitting if varenicline is used as a reduction aid. The analysis comparing reduction using pharmacotherapy with reduction alone found low-certainty evidence, limited by inconsistency and imprecision, that reduction aided by pharmacotherapy resulted in higher quit rates (RR 1. 68, 95% CI 1.09 to 2.58; I2 = 78%; 11 studies, 8636 participants). However, a significant subgroup analysis (P < 0.001, I2 = 80% for subgroup differences) suggests that this may only be true when fast-acting NRT or varenicline are used (both moderate-certainty evidence) and not when nicotine patch, combination NRT or bupropion are used as an aid (all low- orvery low-quality evidence). More evidence is likely to change the interpretation of the latter effects.

Although there was some evidence from within-study comparisons that behavioural support for reduction to quit resulted in higher quit rates than self-help resources alone, the relative efficacy of various other characteristics of reduction-to-quit interventions investigated through within- and between-study comparisons did not provide any evidence that they enhanced the success of reduction-to-quit interventions. Pre-quit AEs, SAEs and nicotine withdrawal symptoms were measured variably and infrequently across studies. There was some evidence that AEs occurred more frequently in studies that compared reduction using pharmacotherapy versus no pharmacotherapy; however, the AEs reported were mild and usual symptoms associated with NRT use. There was no clear evidence that the number of people reporting SAEs, or changes in withdrawal symptoms, differed between trial arms.

Conclusions

There is moderate-certainty evidence that neither reduction-to-quit nor abrupt quitting interventions result in superior long-term quitrates when compared with one another. Evidence comparing the efficacy of reduction-to-quit interventions with no treatment was inconclusive and of low certainty. There is also low-certainty evidence to suggest that reduction-to-quit interventions may be more effective when pharmacotherapy is used as an aid, particularly fast-acting NRT or varenicline (moderate-certainty evidence).

Evidence for any adverse effects of reduction-to-quit interventions was sparse, but available data suggested no excess of pre-quit SAEs or withdrawal symptoms. The authors downgraded the evidence across comparisons due to risk of bias, inconsistency and imprecision. Future research should aim to match any additional components of multicomponent reduction-to-quit interventions across study arms, so that the effect of reduction can be isolated. In particular, well-conducted, adequately-powered studies should focus on investigating the most effective features of reduction-to-quit interventions to maximise cessation rates.